News Release

Aging-US: Prognostic prediction of patients with lung adenocarcinoma

This Aging-US study identified a novel FRG signature that could be used to evaluate and predict the prognosis of LUAD patients

Peer-Reviewed Publication

Impact Journals LLC

Figure 7

image: The relative expression levels of the five genes in normal and LUAD tissues. The ACSL3 (A) was up-regulated significantly and CISD1 (B), NCOA4 (C) and PEBP1 (D) were down-regulated in the LUAD tissues. No significant differences were observed in the PHKG2 (E). *P < 0.05; **P < 0.01, ns: not significant view more 

Credit: Correspondence to: Xiangyang Xue email: wzxxy001@163.com and Fangfang Wu email: mariawu@sina.com

Aging-US published "A novel ferroptosis-related gene signature for prognostic prediction of patients with lung adenocarcinoma" which reported that RNA-seq transcriptome data of LUAD patients were obtained from The Cancer Genome Atlas database.

Kaplan–Meier survival and receiver operating characteristic curves were utilized to assess the prognostic prediction efficiency of the constructed survival model. LUAD patients from the GSE30219 dataset were used for validation.

The authors found that the overall survival of patients in the high-risk group was significantly worse than that of their low-risk counterparts.

In addition, gene set variation analysis of the tumor microenvironment of the two groups may explain the different survival of LUAD patients.

This Aging-US study identified a novel FRG signature that could be used to evaluate and predict the prognosis of LUAD patients, which might provide a new therapeutic target for the treatment of LUAD patients.

Dr. Xiangyang Xue and Dr. Fangfang Wu, both from The Wenzhou Medical University, said, "Lung cancer is one of the leading causes of cancer-related death worldwide and is characterized by high mortality and poor prognosis"

Clinically, non-small cell lung cancer accounts for most of the diagnosed cases of LUAD, and the common histologic type of NSCLC is responsible for ~40% of all lung cancer cases.

Emerging evidence has shown the crucial role of ferroptosis in the regulation of the growth and metastasis of cancers, which suggests its great potential for cancer therapy and prognosis prediction.

BoyiGan and colleagues demonstrated that overexpression of the deubiquitinase ovarian tumor family deubiquitinase ubiquitin aldehyde binding 1 in human cancers can promote tumor progression by regulating the ferroptosis process in cancer cells.

Moreover, with the utilization of bioinformatics techniques, researchers have developed some survival models based on ferroptosis-related genes for the prognostic prediction of cancer patients, including those with glioma, HCC and clear cell renal cell carcinoma.

The Xue/Wu Research Team concluded in their Aging-US Research Output, "a novel prognostic model of 5 ferroptosis-related genes was constructed in this study. This model was shown to be independently associated with OS in both the TCGA and GSE30219 cohorts, providing a candidate model for predicting survival of LUAD patients. Our study may provide insight into the identification of therapeutic targets for LUAD."

Sign up for free Altmetric alerts about this article

DOI - https://doi.org/10.18632/aging.203140

Full Text - https://www.aging-us.com/article/203140/text

Correspondence to: Xiangyang Xue email: wzxxy001@163.com and Fangfang Wu email: mariawu@sina.com

Keywords: ferroptosisFRGslung adenocarcinoma (LUAD)prognosis

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research as well as topics beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, cancer, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR among others), and approaches to modulating these signaling pathways.

To learn more about Aging-US, please visit http://www.Aging-US.com or connect with @AgingJrnl

Aging-US is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
18009220957x105
MEDIA@IMPACTJOURNALS.COM


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.